<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Extraction Schema extraction-schema-7 - Theorizer</title>
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/5.15.1/css/all.min.css">
    <link rel="stylesheet" href="../style.css">
</head>
<body>
    <div class="header">
        <a href="../index.html"><i class="fas fa-flask"></i> Theorizer</a>
    </div>

    <div class="content">
        <h1>Extraction Schema Details for extraction-schema-7</h1>

        <div class="section">
            <h2>Extraction Schema (General Information)</h2>
            <div class="info-section">
                <p><strong>Schema ID:</strong> extraction-schema-7</p>
                <p><strong>Extraction Query:</strong> Extract any mentions of anti-PD-1 therapy duration strategies and outcomes in melanoma, including planned/actual duration, stopping rules, and whether optimal duration differs by depth of response (CR/PR/SD). Capture setting (metastatic vs adjuvant), regimen, response-stratified relapse and survival after stopping, comparisons of stopping vs continuing, biomarkers guiding discontinuation (e.g., PET/ctDNA), retreatment outcomes after relapse, toxicity with prolonged therapy, and any cost-effectiveness or modeling analyses. Prefer concise, numeric, and timepoint-specific results where available.</p>
            </div>
        </div>

        <div class="section">
            <h2>Extraction Schema (Details)</h2>
            <table>
                <thead>
                    <tr>
                        <th style="width: 20%;">Field Name</th>
                        <th style="width: 15%;">Type</th>
                        <th style="width: 65%;">Description</th>
                    </tr>
                </thead>
                <tbody>
                    <tr>
                        <td><strong>study_identifier</strong></td>
                        <td>str</td>
                        <td>Concise identifier for the study (e.g., first author + year, trial name; examples: 'KEYNOTE-006 2021 update', 'Dutch Melanoma Registry 2019', 'DANTE trial protocol').</td>
                    </tr>
                    <tr>
                        <td><strong>paper_title</strong></td>
                        <td>str</td>
                        <td>Full title of the paper.</td>
                    </tr>
                    <tr>
                        <td><strong>year</strong></td>
                        <td>int</td>
                        <td>Publication year (numeric if available).</td>
                    </tr>
                    <tr>
                        <td><strong>doi_or_trial_id</strong></td>
                        <td>str</td>
                        <td>DOI or clinical trial registration ID (e.g., NCT number), if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>study_type</strong></td>
                        <td>str</td>
                        <td>Study design/type (e.g., randomized controlled trial, prospective cohort, retrospective registry, real-world, systematic review/meta-analysis, trial protocol, modeling/cost-effectiveness).</td>
                    </tr>
                    <tr>
                        <td><strong>setting</strong></td>
                        <td>str</td>
                        <td>Disease setting and line of therapy; specify 'metastatic/unresectable' or 'adjuvant' (stage), and first-line vs later-line if reported.</td>
                    </tr>
                    <tr>
                        <td><strong>sample_size</strong></td>
                        <td>str</td>
                        <td>Number of patients overall and number evaluable for discontinuation analyses (e.g., 'n=550 treated; n=185 discontinued electively').</td>
                    </tr>
                    <tr>
                        <td><strong>therapy_regimen</strong></td>
                        <td>str</td>
                        <td>Anti-PD-1 agent(s) and combination details (e.g., 'pembrolizumab 200 mg q3w monotherapy', 'nivolumab ± ipilimumab'). Include dosing if stated.</td>
                    </tr>
                    <tr>
                        <td><strong>anti_pd1_monotherapy</strong></td>
                        <td>bool</td>
                        <td>True if the study arm/data pertain to anti-PD-1 monotherapy only; false if combination or mixed; null if unclear.</td>
                    </tr>
                    <tr>
                        <td><strong>duration_strategy</strong></td>
                        <td>str</td>
                        <td>Planned/actual treatment duration policy (e.g., 'treat until progression/toxicity', 'cap at 2 years', 'stop at confirmed CR after ≥6 months', 'response-adapted stop', 'PET- or ctDNA-guided stop').</td>
                    </tr>
                    <tr>
                        <td><strong>stopping_criteria</strong></td>
                        <td>str</td>
                        <td>Explicit criteria to discontinue (e.g., 'RECIST v1.1 confirmed CR on 2 scans ≥4 weeks apart', 'complete metabolic response on PET', 'grade ≥3 irAE', 'patient choice').</td>
                    </tr>
                    <tr>
                        <td><strong>median_time_on_therapy</strong></td>
                        <td>str</td>
                        <td>Time on therapy before discontinuation (median and range/IQR; include units, e.g., 'median 11.2 months [IQR 7–17]').</td>
                    </tr>
                    <tr>
                        <td><strong>response_at_discontinuation</strong></td>
                        <td>str</td>
                        <td>Distribution of best response at the time of stopping (e.g., 'CR 48%, PR 35%, SD 17%'; specify response criteria such as RECIST/iRECIST if given).</td>
                    </tr>
                    <tr>
                        <td><strong>has_response_stratified_outcomes</strong></td>
                        <td>bool</td>
                        <td>True if outcomes after stopping are reported separately for CR vs PR vs SD; false otherwise.</td>
                    </tr>
                    <tr>
                        <td><strong>outcomes_by_response</strong></td>
                        <td>str</td>
                        <td>Outcomes after discontinuation stratified by CR/PR/SD (relapse/progression rates, PFS/OS/TFS at specified timepoints, medians, HRs). Provide numeric values with units and timepoints (e.g., '12-mo relapse: CR 8%, PR 28%, SD 45%').</td>
                    </tr>
                    <tr>
                        <td><strong>compare_stop_vs_continue</strong></td>
                        <td>str</td>
                        <td>If the study compares elective stopping vs continuing therapy (randomized or observational), summarize arms and key effect sizes (HRs with 95% CIs, absolute risk differences) for PFS/OS/relapse.</td>
                    </tr>
                    <tr>
                        <td><strong>recurrence_rate_after_stop</strong></td>
                        <td>str</td>
                        <td>Overall relapse/progression after elective discontinuation (e.g., cumulative incidence at 12/24/36 months, median time to relapse). Include numbers and units.</td>
                    </tr>
                    <tr>
                        <td><strong>treatment_free_survival</strong></td>
                        <td>str</td>
                        <td>Treatment-free survival metrics after stopping (medians, proportions at timepoints, definitions used).</td>
                    </tr>
                    <tr>
                        <td><strong>re_treatment_outcomes</strong></td>
                        <td>str</td>
                        <td>Outcomes of retreatment/rechallenge after relapse (response rate, disease control rate, PFS/OS upon rechallenge; include regimen and numeric results).</td>
                    </tr>
                    <tr>
                        <td><strong>toxicity_vs_duration</strong></td>
                        <td>str</td>
                        <td>Immune-related adverse events in relation to treatment duration (incidence of late irAEs, grade ≥3 events, discontinuation due to toxicity; any correlation with longer duration).</td>
                    </tr>
                    <tr>
                        <td><strong>biomarkers_guiding_stop</strong></td>
                        <td>str</td>
                        <td>Biomarkers used to guide discontinuation (e.g., PET complete metabolic response, ctDNA negativity) and their predictive performance for relapse (e.g., NPV/PPV, HRs).</td>
                    </tr>
                    <tr>
                        <td><strong>cost_effectiveness</strong></td>
                        <td>str</td>
                        <td>Any economic/cost-effectiveness or modeling analyses comparing durations (e.g., 1 year vs 2 years): costs, QALYs, ICERs, optimal duration estimates.</td>
                    </tr>
                    <tr>
                        <td><strong>follow_up_after_stop</strong></td>
                        <td>str</td>
                        <td>Duration of follow-up after discontinuation (median, range) and minimum required follow-up for inclusion in analyses.</td>
                    </tr>
                    <tr>
                        <td><strong>authors_recommendation</strong></td>
                        <td>str</td>
                        <td>Authors' explicit recommendations or conclusions on optimal duration, including whether it should differ by response category.</td>
                    </tr>
                    <tr>
                        <td><strong>key_limitations</strong></td>
                        <td>str</td>
                        <td>Important limitations/biases impacting interpretation (e.g., selection bias in elective discontinuation, immortal time bias, small numbers in SD subgroup).</td>
                    </tr>
                    <tr>
                        <td><strong>country_or_registry</strong></td>
                        <td>str</td>
                        <td>Geographic context or data source (e.g., Netherlands DMTR, MSKCC, Flatiron, multicenter international).</td>
                    </tr>
                    <tr>
                        <td><strong>notes</strong></td>
                        <td>str</td>
                        <td>Any other relevant details (e.g., inclusion/exclusion of brain metastases, BRAF status effects, imaging schedules, definitions used).</td>
                    </tr>
                </tbody>
            </table>
        </div>

    </div>
</body>
</html>